3Sbio Overview

  • Founded
  • 1993

Founded
  • Status
  • Public

  • Employees
  • 5,160

Employees
  • Stock Symbol
  • 01530

Stock Symbol
  • Investments
  • 15

  • Share Price
  • $1.15

  • (As of Friday Closing)

3Sbio General Information

Description

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

Contact Information

Website
www.3sbio.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
HKG
Primary Office
  • 1st 3, 10th Road
  • Economic and Technological Development Zone
  • Shenyang, Liaoning
  • China
+86 024 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

3Sbio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.15 $1.14 $0.60 - $1.16 $2.78B 2.44B 16.1M $0.11

3Sbio Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 2,061,814 2,162,132 2,418,550 3,560,269
Revenue 985,293 988,374 808,793 769,663
EBITDA 348,297 335,390 193,473 232,014
Net Income 264,168 255,727 120,978 140,922
Total Assets 3,062,056 3,014,163 2,705,860 2,116,583
Total Debt 573,418 412,431 446,041 401,816
Public Fundamental Data provided by Morningstar, Inc. disclaimer

3Sbio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 3Sbio‘s full profile, request access.

Request a free trial

3Sbio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenu
Pharmaceuticals
Shenyang, China
5,160 As of 2022
00000
00000000 00000

0000 0

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
000000000000000
Petah Tikva, Israel
00000 As of 0000
00000
00000000000 00000

000000

tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Suzhou, China
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

3Sbio Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Teva Pharmaceutical Industries Corporate Backed or Acquired Petah Tikva, Israel 00000 00000 00000000000 00000
00000000 000000000 Formerly PE-Backed Suzhou, China 0000 00.000 000000000 00.000
You’re viewing 2 of 2 competitors. Get the full list »

3Sbio Executive Team (6)

Name Title Board Seat Contact Info
Jing Lou Ph.D Chief Executive Officer & Chairman
Bo Tan Chief Financial Officer, Executive Vice President and Executive Director
Weihong Xiao Chief Operating Officer
Lu Xia Director, Investor Relations
Thomas Folinsbee Division Director, Corporate Development of Strategic Investment
You’re viewing 5 of 6 executive team members. Get the full list »

3Sbio Board Members (2)

Name Representing Role Since
0000 000 00.0 3Sbio Chief Executive Officer & Chairman 000 0000
00 0000 3Sbio Board Member 000 0000
To view 3Sbio’s complete board members history, request access »

3Sbio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

3Sbio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 3Sbio‘s full profile, request access.

Request a free trial

3Sbio Investments & Acquisitions (15)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 21-Oct-2019 00000 0000 0000 Drug Discovery 00000000
0000000 00000 12-Feb-2019 00000 0000 0000 Drug Discovery 00000000
000000 000000 02-May-2018 00000 0000 0000 Drug Discovery 0000 000
000000 000000 01-Dec-2017 00 0000000 000.00 Biotechnology 0000 000
Therapure Biopharma (Contract Development & Manufacturing Assets) 03-Sep-2017 Merger/Acquisition 00000 Biotechnology 0000 000
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

3Sbio Subsidiaries (2)

Company Name Industry Location Founded
Sciprogen Bio-pharmaceutical Other Pharmaceuticals and Biotechnology Shenzhen, China 1999
000000 00000000000 Drug Delivery Villa Guardia, Italy 0000
To view 3Sbio’s complete subsidiaries history, request access »

3Sbio ESG

Risk Overview

Risk Rating

Updated March, 11, 2022

27.12 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view 3Sbio’s complete esg history, request access »

3Sbio Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 000000 11-Feb-2010 000000000 000 Completed
  • 00000
You’re viewing 1 of 2 exits. Get the full list »